Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low – Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares reached a new 52-week low on Monday . The stock traded as low as $15.83 and last traded at $15.95, with a volume of 61229 shares traded. The stock had previously closed at $16.69.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target for the company. TD Cowen initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright assumed coverage on Bicara Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $42.00 price target on the stock. Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective for the company. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Stock Down 3.2 %

The firm has a fifty day moving average price of $19.81.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. First Turn Management LLC bought a new position in shares of Bicara Therapeutics during the third quarter worth approximately $14,324,000. Vestal Point Capital LP acquired a new stake in shares of Bicara Therapeutics during the third quarter valued at about $10,825,000. FMR LLC bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $57,913,000. Braidwell LP acquired a new position in Bicara Therapeutics during the 3rd quarter worth about $42,219,000. Finally, Point72 Asset Management L.P. bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $9,474,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.